E. Garry Menzel - Dec 1, 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC. (TCRR)

Signature
Margaret Siegel as Attorney-in-Fact
Stock symbol
TCRR
Transactions as of
Dec 1, 2022
Transactions value $
-$11,687
Form type
4
Date filed
12/5/2022, 06:49 PM
Previous filing
Nov 18, 2022
Next filing
Dec 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Options Exercise +221K 221K Dec 1, 2022 Direct F3, F4
transaction TCRR Common Stock Sale -$11.7K -8.41K -3.8% $1.39 213K Dec 2, 2022 Direct F5
holding TCRR Common Stock 133K Dec 1, 2022 See Footnote F1
holding TCRR Common Stock 133K Dec 1, 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Restricted Stock Unit Options Exercise $0 +159K $0.00 3.24K Dec 1, 2022 Common Stock 159K Direct F4, F6
transaction TCRR Restricted Stock Unit Options Exercise $0 +40.9K $0.00 15.1K Dec 1, 2022 Common Stock 40.9K Direct F4, F7
transaction TCRR Restricted Stock Unit Options Exercise $0 +21.4K +1199.21% $0.00 23.2K Dec 1, 2022 Common Stock 21.4K Direct F4, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 132,729 shares of common stock held by the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
F2 Consists of 132,730 shares of common stock held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
F3 Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.
F4 Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
F5 The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
F6 98% of these restricted stock units vested on December 1, 2022, and the remaining 2% will vest on December 1, 2023.
F7 73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.
F8 48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.